Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 5Phase 2 5Phase 1/2 3Phase 1 3Phase EARLY_PHASE1 2

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Carcinoma, Non-Small-Cell Lung 147Breast Neoplasms 116Prostatic Neoplasms 61Multiple Myeloma 57Neoplasms 56Lung Neoplasms 50Neoplasm Metastasis 43Ovarian Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 35Colorectal Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Renal Cell 27Recurrence 26Leukemia, Myeloid, Acute 26Urinary Bladder Neoplasms 25Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 23Myasthenia Gravis 22Triple Negative Breast Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Endometrial Neoplasms 20Melanoma 19Lymphoma, Follicular 19Nasopharyngeal Carcinoma 18Fallopian Tube Neoplasms 18Stomach Neoplasms 17Non-Muscle Invasive Bladder Neoplasms 16Brain Neoplasms 16Pancreatic Neoplasms 15

Interventions

Dexamethasone 3Cyclophosphamide 3Bortezomib 3Clinical Protocols 2dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Stem Cell Transplantation 1Specimen Handling 1Melphalan 1Magnetic Resonance Spectroscopy 1Calcium Dobesilate 1Biopsy 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Immunoglobulin Light-chain Amyloidosis × 90 days × Clear all
NCT05184088 2026-06-02

CArdiag

Lantheus Biosciences Ltd.

Phase 3 Completed
244 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial

NCT06963216 2026-05-11

A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis

Kedrion S.p.A.

Phase 3 Recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Blood Coagulation Disorders, Factor X Deficiency, Hematologic Diseases, Hemorrhagic Disorders

NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡